PCI for Myocardial Bridging
PCI is generally NOT recommended as first-line treatment for myocardial bridging; medical therapy with beta-blockers is the primary approach, with PCI reserved only for highly selected symptomatic patients who fail maximal medical therapy and have documented ischemia by physiologic testing and intravascular imaging guidance.
Management Algorithm
Step 1: Initial Assessment and Risk Stratification
The vast majority of myocardial bridging cases are benign anatomical variants requiring no intervention 1, 2. Your first task is determining if the MB is clinically significant:
- Asymptomatic MB discovered incidentally: No treatment needed 1, 2
- Symptomatic patients: Proceed to physiologic assessment before considering any intervention
Step 2: Medical Therapy First-Line
Beta-blockers are the cornerstone of treatment for symptomatic MB 3, 2. They reduce heart rate and myocardial contractility, decreasing systolic compression of the tunneled segment. Medical management should be maximized before considering any invasive approach 4.
Step 3: When to Consider PCI (Highly Selective)
PCI should only be considered in the following specific scenario:
- Patient remains symptomatic despite maximal medical therapy (primarily beta-blockers) 4
- Documented ischemia attributable to the MB through physiologic testing (FFR/iFR) 3
- Intravascular imaging confirmation (IVUS or OCT) of the mechanism and anatomy 4, 3
- Absence of alternative explanations for symptoms (microvascular dysfunction, vasospasm ruled out) 3
Step 4: Critical Technical Considerations for PCI
If PCI is pursued, the following are mandatory 4, 5, 3:
- IVUS or OCT guidance to precisely define landing zones and optimize stent deployment 4, 3
- High-pressure stent deployment to provide adequate radial strength against systolic compression 5
- Avoid stenting the bridge itself when possible—treat adjacent atherosclerotic disease with precise landing-zone selection 3
- Recognize that stent fracture and restenosis risks are elevated in bridged segments due to repetitive mechanical stress 5, 2
Important Caveats and Pitfalls
The Stenting Paradox
Stenting within the myocardial bridge carries significant risk of stent fracture and restenosis due to repetitive systolic compression 5, 2. This is why traditional teaching advises against PCI for MB. However, recent case series suggest acceptable outcomes when performed with rigorous physiologic assessment and intravascular imaging guidance 4, 3.
When PCI May Be Necessary Despite Risks
In rare acute presentations—particularly plaque rupture within or proximal to the bridge causing STEMI—PCI becomes necessary despite the technical challenges 6, 5. In these cases:
- Treat the culprit lesion (usually proximal to the bridge) 6
- Use intravascular imaging to confirm plaque rupture location 5
- Accept the stent fracture risk when clinical imperative demands intervention 5
Surgical Myotomy as Alternative
For patients with refractory symptoms who fail medical therapy, surgical unroofing (myotomy) remains an alternative to PCI, particularly for deep or long bridges 4, 7. This avoids the stent-related complications but requires cardiac surgery.
The Role of Comprehensive Physiologic Testing
Modern assessment should include 3:
- Dobutamine stress testing to unmask hemodynamic significance
- Acetylcholine testing to identify concurrent vasospasm
- Microvascular function assessment to exclude microvascular dysfunction as the primary mechanism
This integrated approach prevents misattribution of symptoms solely to the MB when other mechanisms coexist 3.
Evidence Strength and Limitations
No high-quality randomized trials exist comparing PCI vs. medical therapy vs. surgery for symptomatic MB. The evidence base consists primarily of case series and observational data 4, 5, 3. The 2024 ESC and 2022 ACC/AHA revascularization guidelines 8, 9 do not specifically address MB, as it falls outside the scope of obstructive coronary disease requiring revascularization for prognostic benefit.
The recent case series showing favorable PCI outcomes 4, 3 must be interpreted cautiously—these represent highly selected patients treated at experienced centers with meticulous technique. The 2-7 year follow-up data from one series 4 is encouraging but limited by small numbers and potential publication bias.